Gastrointestinal symptoms are clinical features of Huntington’s disease (HD), which adversely affect people’s quality of life. We recently reported the first evidence of gut dysbiosis in HD gene expansion carriers (HDGECs). Here, we report on a randomized controlled clinical trial of a 6-week probiotic intervention in HDGECs.
Objective:
The primary objective was to determine whether probiotics improved gut microbiome composition in terms of richness, evenness, structure, and diversity of functional pathways and enzymes. Exploratory objectives were to determine whether probiotic supplementation improved cognition, mood, and gastrointestinal symptoms.
Methods:
Forty-one HDGECs, including 19 early manifest and 22 premanifest HDGECs were compared with 36 matched-healthy controls (HCs). Participants were randomly assigned probiotics or placebo and provided fecal samples at baseline and 6-week follow-up, which were sequenced using 16S-V3-V4 rRNA to characterize the gut microbiome. Participants completed a battery of cognitive tests and self-report questionnaires measuring mood and gastrointestinal symptoms.
Results:
HDGECs had altered gut microbiome diversity when compared to HCs, indicating gut dysbiosis. Probiotic intervention did not ameliorate gut dysbiosis or have any effect on cognition, mood, or gastrointestinal symptoms. Gut microbiome differences between HDGECs and HCs were unchanged across time points, suggesting consistency of gut microbiome differences within groups.
Conclusion:
Despite the lack of probiotic effects in this trial, the potential utility of the gut as a therapeutic target in HD should continue to be explored given the clinical symptomology, gut dysbiosis, and positive results from probiotics and other gut interventions in similar neurodegenerative diseases.
van der BurgJM, BjorkqvistM, BrundinPBeyond the brain: Widespread pathology in Huntington’s disease. Lancet Neurol2009; 8 (8): 765–74.
2.
AndrichJE, WobbenM, KlotzP, GoetzeO, SaftCUpper gastrointestinal findings in Huntington’s disease: Patients suffer but do not complain, J Neural Transm (Vienna)2009; 116 (12): 1607–11.
3.
KongG, CaoKL, JuddLM, LiS, RenoirT, HannanAJMicrobiome profiling reveals gut dysbiosis in a transgenic mouse model of Huntington’s disease, Neurobiol Dis2020; 135, 104268.
4.
WasserCI, MerciecaEC, KongG, HannanAJ, McKeownSJ, Glikmann-JohnstonY, et al. Gut dysbiosis in Huntington’s disease: Associations among gut microbiota, cognitive performance and clinical outcomes, Brain Commun2020; 2 (2): fcaa110.
5.
DinanTG, StillingRM, StantonC, CryanJFCollective unconscious: How gut microbes shape human behavior, J Psychiatr Res2015; 63, 1–9.
6.
CryanJF, O’RiordanKJ, SandhuK, PetersonV, DinanTGThe gut microbiome in neurological disorders, Lancet Neurol2020; 19 (2): 179–94.
7.
DumitrescuL, Popescu-OlaruI, CozmaL, TulbaD, HinescuME, CeafalanLC, et al. Oxidative stress and the microbiota-gut-brain axis, Oxid Med Cell Longev2018; 2406594;.
8.
CantarelBL, WaubantE, ChehoudC, KuczynskiJ, DeSantisTZ, WarringtonJ, et al. Gut microbiota in multiple sclerosis: Possible influence of immunomodulators, J Investig Med2015; 63 (5): 729–34.
9.
TankouSK, RegevK, HealyBC, TjonE, LaghiL, CoxLM, et al. A probiotic modulates the microbiome and immunity in multiple sclerosis, Ann Neurol2018; 83 (6): 1147–61.
10.
RijkersGT, de VosWM, BrummerRJ, MorelliL, CorthierG, MarteauPHealth benefits and health claims of probiotics: Bridging science and marketing, Br J Nutr2011; 106 (9): 1291–6.
11.
EslamparastT, EghtesadS, HekmatdoostA, PoustchiHProbiotics and nonalcoholic fatty liver disease, Middle East J Dig Dis2013; 5 (3): 129–36.
12.
WestfallS, LomisN, KahouliI, DiaSY, SinghSP, PrakashSMicrobiome, probiotics and neurodegenerative diseases: Deciphering the gut brain axis, Cell Mol Life Sci2017; 74 (20): 3769–87.
13.
BarichellaM, PacchettiC, BolliriC, CassaniE, IorioL, PusaniC, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT, Neurology2016; 87 (12): 1274–80.
14.
TamtajiOR, TaghizadehM, Daneshvar KakhakiR, KouchakiE, BahmaniF, BorzabadiS, et al. Clinical and metabolic response to probiotic administration in people with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial, Clin Nutr2019; 38 (3): 1031–5.
15.
GazeraniPProbiotics for Parkinson’s disease, Int J Mol Sci2019; 20 (17): 4121.
16.
AkbariE, AsemiZ, Daneshvar KakhakiR, BahmaniF, KouchakiE, TamtajiOR, et al. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: A randomized, double-blind and controlled trial, Front Aging Neurosci2016; 8, 256.
17.
TamtajiOR, KouchakiE, SalamiM, AghadavodE, AkbariE, Tajabadi-EbrahimiM, et al. The effects of probiotic supplementation on gene expression related to inflammation, insulin, and lipids in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial, J Am Coll Nutr2017; 36 (8): 660–5.
18.
ShoulsonI, FahnSHuntington disease: Clinical care and evaluation, Neurology1979; 29 (1): 1–3.
19.
KieburtzK, PenneyJB, CornoP, RanenN, ShoulsonI, FeiginA, et al. Unified Huntington’s disease rating scale: Reliability and consistency, Neurology2001; 11 (2): 136–42.
20.
ZhangY, LongJD, MillsJA, WarnerJH, LuW, PaulsenJS, et al. Indexing disease progression at study entry with individuals at-risk for Huntington disease, Am J Med Genet B Neuropsychiatr Genet2011; 156B (7):
751–63.
21.
EppingEA, MillsJA, BeglingerLJ, FiedorowiczJG, CraufurdD, SmithMM,et al. Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study, J Psychiatr Res2013; 47 (10): 1423–31.
22.
SchulzKF, AltmanDG, MoherD, Consort GrouCONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trialsBMC Med2010; 8 (11): 18.
23.
World Medical AssociationWorld Medical Associa-tion Declaration of Helsinki: Ethical principles for medical research involving human subjects, JAMA2013; 310 (20): 2191–4.
24.
Sassone-CorsiM, RaffatelluMNo vacancy: How beneficial microbes cooperate with immunity to provide colonization resistance to pathogens, J Immunol2015; 194 (9): 4081–7.
25.
FosterJA, McVey NeufeldKAGut-brain axis: How the microbiome influences anxiety and depression, Trends Neurosci2013; 36 (5): 305–12.
26.
EatonWW, SmithC, YbarraM, MuntanerC, TienACenter for Epidemiologic Studies Depression Scale: Review and revision (CESD and CESD-R) 2004.
27.
HoldnackH Wechsler test of adult reading: WTAR, San Antonio, TX: The Psychological Corporation 2001.
28.
StoutJC, QuellerS, BakerKN, CowlishawS, SampaioC, Fitzer-AttasC, et al. HD-CAB: A cognitive assessment battery for clinical trials in Huntington’s disease 1,2,3, Mov Disord2014; 29 (10): 1281–8.
29.
BenedictRHB, SchretlenD, GroningerL, BrandtJHopkins Verbal Learning Test –Revised: Normative data and analysis of inter-form and test-retest reliability, Clin Neuropsychol2010; 12 (1): 43–55.
StoutJC, PaulsenJS, QuellerS, SolomonAC, WhitlockKB, CampbellJC, et al. Neurocognitive signs in prodromal Huntington disease, Neuropsychology2011; 25 (1): 1–14.
34.
JohnsonSA, StoutJC, SolomonAC, LangbehnDR, AylwardEH, CruceCB,et al. Beyond disgust: Impaired recognition of negative emotions prior to diagnosis in Huntington’s disease, Brain2007; 130 (Pt 7): 1732–44.
35.
WatkinsLH, RogersRD, LawrenceAD, SahakianBJ, RosserAE, RobbinsTWImpaired planning but intact decision making in early Huntington’s disease: Implications for specific fronto-striatal pathology, Neuropsychologia2000; 38 (8): 1112–25.
McMurdiePJ, HolmesSPhyloseq: An R package for reproducible interactive analysis and graphics of microbiome census data, PLoS One2013; 8 (4): e61217.
38.
DixonPVEGAN, a package of R functions for community ecology, J Veg Sci2003; 14 (6): 927–30.
39.
CaporasoJG, KuczynskiJ, StombaughJ, BittingerK, BushmanFD, CostelloEK,et al. QIIME allows analysis of high-throughput community sequencing data, Nat Methods2010; 7 (5): 335–6.
40.
MandalS, Van TreurenW, WhiteRA, EggesboM, KnightR, PeddadaSDAnalysis of composition of microbiomes: A novel method for studying microbial composition, Microb Ecol Health Dis2015; 26 (1): 27663.
41.
DouglasGM, MaffeiVJ, ZaneveldJ, YurgelSN, BrownJR, TaylorCM,et al. 2020; PICRUSt An improved and customizable approach for metagenome inference, BioRxiv2, 672295.
42.
WangH, LeeIS, BraunC, EnckPEffect of Probiotics on central nervous system functions in animals and humans: A systematic review, J Neurogastroenterol Motil2016; 22 (4): 589–605.
43.
van der BurgJM, WinqvistA, AzizNA, Maat-SchiemanML, RoosRA, BatesGP,et al. Gastrointestinal dysfunction contributes to weight loss in Huntington’s disease mice, Neurobiol Dis2011; 44 (1): 1–8.
44.
WalshKT, ZemperAEThe enteric nervous system for epithelial researchers: Basic anatomy, techniques, and interactions with the epithelium, Cell Mol Gastroenterol Hepatol2019; 8 (3): 369–78.
45.
KellerJ, LayerPThe pathophysiology of malabsorption, Viszeralmedizin2014; 30 (3): 150–4.
46.
MorovicW, HibberdAA, ZabelB, BarrangouR, StahlBGenotyping by PCR and high-throughput sequencing of commercial probiotic products reveals composition biases, Front Microbiol2016; 7, 1747.
47.
FranzosaEA, HsuT, Sirota-MadiA, ShafquatA, Abu-AliG, MorganXC,et al. Sequencing and beyond: Integrating molecular ‘omics’ for microbial community profiling, Nat Rev Microbiol2015; 13 (6): 360–72.
48.
O’ToolePW, ClaessonMJGut microbiota: Changes throughout the lifespan from infancy to elderly, Int Dairy J2010; 20 (4): 281–91.
49.
WangS, XiaoY, TianF, ZhaoJ, ZhangH, ZhaiQ,et al. Rational use of prebiotics for gut microbiota alterations: Specific bacterial phylotypes and related mechanisms, J Funct Foods2020; 66, 103838.
50.
GoldmanJSGenetic testing and counseling in the diagnosis and management of young-onset dementias, Psychiatr Clin North Am2015; 38 (2): 295–308.
